All Industries

Standard Uranium reached agreement to option its Atlantic Project in the Athabasca Basin

Standard Uranium Ltd

Standard Uranium CEO Jon Bey joined Steve Darling from Proactive to unveil a significant development for the company: the signing of a term sheet with ATCO Mining, enabling them to acquire a seventy-five percent interest in the 3,061-hectare Atlantic Project situated in the eastern Athabasca Basin. This marks the company's fourth option agreement and positions Standard Uranium as the operator of the project. With over thirty million dollars committed to exploration programs over the next three years and nine million dollars dedicated to exploration in 2024, Standard Uranium is poised for significant advancement. In addition to this milestone, Bey disclosed that the company has made another strategic move through the acquisition of the Harrison uranium exploration project in the southwest Athabasca Basin region of Northern Saskatchewan. Through staking, the Ascent project has been expanded by 3,728 hectares, effectively doubling its size. This expansion brings the company's ownership interests to eleven exploration properties, totaling over 209,867 acres across the uranium-rich Athabasca Basin. Notably, the Harrison project presents a compelling opportunity as it has never undergone drill testing, offering Standard Uranium additional exploration exposure in the southwest Athabasca uranium district. These developments underscore Standard Uranium's strategic focus on expanding its exploration portfolio and advancing its presence in key uranium-rich regions. With a robust exploration budget and an expanded project portfolio, the company is well-positioned to capitalize on opportunities in the uranium market. Stay tuned for further updates as Standard Uranium continues its exploration efforts and seeks to unlock significant value for its stakeholders in the dynamic uranium sector. Contact Details Proactive Canada +1 604-688-8158 action@proactiveinvestors.com

February 20, 2024 10:56 AM Eastern Standard Time

Video

Volta Metals assay results from drilling at Falcon West shows high-grade Lithium Zones

Volta Metals Ltd

Volta Metals CEO Kerem Usenmez joined Steve Darling from Proactive to announce the release of assay results from 11 drill holes completed during the inaugural drill program at the Falcon West Lithium Property, situated in northwestern Ontario, Canada. The assay results revealed the presence of near-surface spodumene-albite pegmatite-hosted lithium, cesium, and tantalum mineralization, with potential for expansion. Usenmez explains that the initial drilling was strategically designed to test the five spodumene-bearing pegmatites identified during Volta's 2023 exploration program, which covered a small section of the vast 13km² property. Remarkably, all 11 boreholes successfully intercepted mineralization in five known pegmatites, with hole FW23-07 encountering blind pegmatite from 47.4m to 59.1m, before concluding at 60.1m depth. The success of the drilling campaign underscores the significant potential of the Falcon West Lithium Project. The data obtained will empower Volta's exploration team to enhance their understanding of the structural orientations of the pegmatites and refine drill-hole design for the upcoming 2024 exploration program. Furthermore, the high-grade lithium results, coupled with strongly anomalous cesium and tantalum, indicate the presence of a substantial LCT mineralized system within the Falcon West Project. Currently, the company is in the final stages of finalizing its 2024 exploration program, which will encompass diamond drilling, mechanized trenching, and additional geochemical sampling. This comprehensive approach underscores Volta Metals' commitment to advancing exploration efforts and unlocking the full potential of the Falcon West Lithium Project. Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

February 20, 2024 10:51 AM Eastern Standard Time

Video

REEP Equity to Host Webinar About Multifamily Trends & Strategies for 2024

REEP Equity

Real Estate Equity Partners ( REEP Equity ) announced “ Unraveling the Multifamily Market: Trends & Strategies for 2024,” a live webinar that will take place on February 29, 2024. Anyone curious about investing in multifamily real estate in Texas is invited to register for the free event and tune in at 7:00 p.m. CST to learn from REEP Equity founders Jacob and Arleen Garza, as well as special guest Mark Brandenburg, Senior Managing Director at JLL Capital Markets. Those with questions about the multifamily market, seeking emerging investment opportunities in Texas, or those hoping to better understand fluctuating interest and cap rates are invited to attend. Webinar attendees can expect to learn the following: The benefits of multifamily investing with a trusted operator The economic forces that drive the Texas multifamily market and how Texas differs from the national market Owner strategies for buying and financing deals in the current market Market dynamics and how the ever-shifting trends can inform and help your investment strategies “There is so much noise in the media about multifamily. Many are unsure what to believe or who to trust. We’re excited to pull back the curtain for curious investors and share our thoughts and insights to help provide clarity,” said Jacob Garza, Founder of REEP Equity. “We often get asked, ‘Is multifamily in Texas a good investment? What great opportunities are you seeing?’ and ‘What strategies do you recommend for the best returns?’ We’ll answer these questions and more on February 29,” said Arleen Garza, Founder of REEP Equity. REEP Equity was founded in 2012 by Jacob and Arleen Garza, who are experts in acquiring multifamily properties in Texas that are underperforming but nevertheless generate income. Since its founding, REEP Equity has bought, sold, and managed $720M worth of multifamily assets across San Antonio, Houston, and Austin. The company has taken nine properties full cycle, with an average historical investor return of 2.17 x equity multiple, an average of 24% IRR, and 34% AAR. Its current portfolio includes 23 properties with a total of 4,171 units. Mark Brandenburg is a Senior Managing Director in the Dallas office of JLL Capital Markets, Americas. He has been involved in commercial real estate since 2000, with his primary area of responsibility being the capitalization of commercial real estate, including multi-housing, office, retail, industrial, mixed-use, hotels, seniors housing, and self-storage. Mark has facilitated structured finance solutions in conventional permanent financings, joint ventures, mezzanine debt, bridge loans, and construction financing. Over his time with JLL, Mark’s direct transactional experience exceeds $3.5 billion. The webinar is free to attend. Learn more and save your spot here. To learn more about REEP Equity, visit Reepequity.com. To learn more about JLL Capital Markets, visit us.jll.com. About Real Estate Equity Partners Real Estate Equity Partners (REEP Equity) is focused on acquiring underperforming, income-producing, multifamily investment opportunities in Texas. Headquartered in San Antonio, REEP Equity is vertically integrated with its in-house management company, REEP Residential, and this unique setup allows the two enterprises to work together, ensuring that the entire acquisition process is effectively managed, thereby creating value for investors while improving tenants' lives. Since its establishment, REEP Equity has bought, sold, and managed 5,500+ units, taking nine properties full cycle. About JLL Capital Markets For over 200 years, JLL Capital Markets (NYSE: JLL), a leading global commercial real estate and investment management company, has helped clients buy, build, occupy, manage, and invest in a variety of commercial, industrial, hotel, residential and retail properties. A Fortune 500 company with annual revenue of $20.9 billion and operations in over 80 countries around the world, its more than 103,000 employees bring the power of a global platform combined with local expertise. Driven by the company’s purpose to shape the future of real estate for a better world, they help their clients, people, and communities SEE A BRIGHTER WAY SM. Contact Details Ilissa Goldenberg +1 973-769-6108 ilissa@rprfirm.com Company Website https://reepequity.com/

February 20, 2024 10:50 AM Eastern Standard Time

Elutia's CanGarooRM: Pioneering Drug-Eluting Biologic for Secure Medical Implants

Elutia Inc.

Elutia CEO Randy Mills joined Steve Darling from Proactive to discuss the company's groundbreaking product, CanGarooRM, a drug-eluting biologic designed to safeguard implanted medical devices such as pacemakers. Founded by Mills and Kevin Rakin, both esteemed veterans in the biotech industry, Elutia aims to revolutionize healthcare by combining regenerative medicine with localized drug delivery. Mills shed light on CanGarooRM's unique formulation, which includes antibiotics to prevent infections and device migration, ultimately enhancing patient safety. With the FDA accepting their filing in December, Elutia is optimistic about receiving favorable results in the second quarter of this year. If approved, CanGarooRM has the potential to capture a significant share of the market, estimated to exceed $500 million. Mills further elaborated that Elutia has completed product development and is poised to commence commercial production by the late second quarter. A soft launch is planned for the third quarter, followed by full-scale deployment by the fourth quarter of this year. This strategic timeline positions Elutia for substantial growth pending regulatory approval, with CanGarooRM poised to address critical needs in the healthcare industry and improve patient outcomes. In summary, the interview underscored Elutia's promising trajectory and the transformative potential of CanGarooRM in enhancing medical device safety. With a strong foundation in regenerative medicine and localized drug delivery, Elutia is poised to make a significant impact in healthcare innovation, driving positive change and improving patient care globally. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:37 AM Eastern Standard Time

Video

Hive Digital sees 146% increase in Gross Operating Margins as company releases Q3 earnings report

HIVE Digital Technologies

Hive Digital Technologies CEO Aydin Kilic joined Steve Darling from Proactive to announce the company's earnings report for the third quarter. Kilic revealed that the company achieved remarkable revenue of $30.1 million during this quarter, primarily attributed to mining 830 Bitcoin. Notably, the Gross Operating Margin stood at an impressive 38%, translating to $11.3 million in income from digital currency mining operations. Kilic highlighted that these figures represent a significant 146% increase in Gross Operating Margin compared to the previous quarter. He attributed the stronger Bitcoin mining economics to the rally in Bitcoin prices, potentially fuelled by the news surrounding Bitcoin ETFs in the United States and the subsequent SEC approval on January 10, 2024. In addition to revenue from Bitcoin mining, the company realized $0.9 million in revenue during the quarter from its GPU-powered High Performance Computing business unit. This segment leverages the company's GPUs for various AI computations, including inference and fine-tuning of large language models. Overall, these impressive financial results underscore Hive Digital Technologies' strong performance in the cryptocurrency mining sector and its strategic diversification into other high-growth areas such as AI computation. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:32 AM Eastern Standard Time

Video

Simply Solventless Concentrates announces new VP as company plans 2024 products launch

Simply Solventless Concentrates

Simply Solventless Concentrates CEO Jeff Swainson joins Steve Darling from Proactive to share exciting updates regarding the company's upcoming activities. Simply Solventless Concentrates anticipates a busy month ahead, with approximately $1.25 million in purchase orders lined up from Alberta and Ontario. Additionally, the company is set to launch six third-party branded products in Alberta and one in Ontario, further expanding its market presence. Swainson underscored the importance of strategic leadership in supporting the company's growth trajectory. To this end, Simply Solventless Concentrates announced the appointment of Jeff Lawrence to the position of Vice President, Marketing & Sales. Lawrence brings over 30 years of experience in industrial and consumer packaged goods, including five years in the cannabis industry. With a proven track record of driving sales growth and propelling startups through strategic development, team building, and effective leadership, Lawrence is poised to make a significant impact on the company's sales and marketing initiatives. Swainson highlighted Lawrence's previous role as National Director of Sales at Dycar Pharmaceuticals, where he played a key role in overseeing the launch of four brands and scaling store listings from 70 to over 2,200 across five provinces. Lawrence's extensive experience and leadership acumen make him a valuable addition to the Simply Solventless Concentrates team, positioning the company for continued success and expansion in the competitive cannabis market. With a robust pipeline of purchase orders and new product launches on the horizon, Simply Solventless Concentrates is primed for growth under Lawrence's leadership. Stay tuned for further updates as the company continues to execute its strategic initiatives and capitalize on emerging opportunities in the cannabis industry. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:29 AM Eastern Standard Time

Video

CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board

CervoMed

CervoMed Inc CEO John Alam joined Steve Darling from Proactive to announce a significant addition to the company's leadership team. CervoMed has appointed Joshua Boger to its Board of Directors as Chair, leveraging his wealth of experience in drug development and biopharmaceutical leadership to drive the company's strategic initiatives forward. Dr. Boger is a seasoned industry veteran with over 40 years of experience, renowned for his innovative approach to science and proven track record as a business executive. Currently serving as Executive Chairman of Alkeus Pharmaceuticals, Dr. Boger brings invaluable insights and expertise to CervoMed. Alam elaborated on the significance of Dr. Boger's appointment and the pivotal phase the company is entering, with topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod in dementia with Lewy bodies (DLB) expected in the second half of 2024. Neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha, holds immense promise in addressing synaptic dysfunction, particularly in the basal forebrain cholinergic system, which is most impacted in DLB. Drawing from preclinical studies and clinical trials involving over 300 participants, Alam highlighted neflamapimod's favorable safety profile and its significant impact on dementia severity as demonstrated in the AscenD-LB Phase 2a clinical study. These promising results underscore the potential of neflamapimod to address the unmet medical needs in DLB and pave the way for transformative treatment options. The appointment of Dr. Boger and the advancements in CervoMed's clinical trials signify a significant milestone in the company's mission to develop innovative therapies for neurodegenerative diseases. With a visionary leadership team and a promising pipeline of treatments, CervoMed is poised to make a meaningful impact on the lives of patients and caregivers affected by DLB and related conditions. Stay tuned for further updates as CervoMed continues its journey towards advancing neurological healthcare. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:22 AM Eastern Standard Time

Video

Madison Metals announces high-grade discover at Anomaly 5 at Khan Project

Madison Metals Inc

Madison Metals CEO Duane Parnham joined Steve Darling from Proactive to unveil a significant milestone in the company's exploration efforts. Madison Metals has made a remarkable discovery of high-grade uranium mineralization at Anomaly 5, located within the Company’s Khan Project in Namibia. The findings, highlighted by a surface sample boasting 8.47% U3O8, mark a substantial expansion of new uranium mineralization, effectively extending Madison’s footprint and project pipeline. During the interview, Parnham elaborated on Madison's exploration strategy, which commenced with the initial fieldwork to ground-truth airborne radiometric anomalies. This groundwork paved the way for follow-up exploration activities, which included the excavation of seven surface rock-saw trenches, leucogranite mapping, sampling, and handheld scintillometer and spectrometer readings at Anomaly 5. The initial batch of assay results from 10 samples returned promisingly high uranium grades, further bolstering the company's confidence in the potential of Anomaly 5. Parnham emphasized that Madison Metals plans to release additional assay results as they become available, providing stakeholders with further insights into the extent and significance of the discovered mineralization. The discovery of high-grade uranium mineralization at Anomaly 5 represents a pivotal moment for Madison Metals, reaffirming the company's commitment to unlocking the full potential of its projects in Namibia. With a strategic focus on exploration and a track record of delivering results, Madison Metals is well-positioned to capitalize on the growing demand for uranium and solidify its position as a key player in the global mining sector. Stay tuned for further updates as the company's exploration efforts continue to unfold. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:16 AM Eastern Standard Time

Video

Cloud DX secures key partnership with Sanrai International for worldwide distribution

Cloud DX

Cloud DX CEO Robert Kaul joined Steve Darling from Proactive to announce a new Partnership Agreement with New York-based Sanrai International. Sanrai International, a leading medical device distribution company with a global presence, will now market and resell the Cloud DX Connected Health platform across more than 65 countries. Kaul highlighted the significance of this partnership, emphasizing Sanrai's extensive customer and sub-distributor network, which spans Latin America, Africa, the Middle East, Asia, and beyond. The focus of this collaboration will be on addressing chronic disease management and post-surgical recovery, leveraging Cloud DX's innovative Connected Health products and services. With the partnership in place, both Cloud DX and Sanrai aim to equalize access to innovative medical devices, particularly in the areas of chronic illness and post-surgical recovery. Kaul also mentioned that Cloud DX has already announced over $2.5 million CAD in new business in 2024, reflecting the company's continued growth and market expansion efforts. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

February 20, 2024 10:06 AM Eastern Standard Time

Video

1 ... 434 435 436 437 438 ... 3787

Back